Diabetic nephropathy is accompanied by the metabolic syndrome 5 and is also the strongest risk factor for cardiovascular outcomes in patients with type 1 diabetes. Pathophysiology, Evaluation and Management is a gold-standard level reference for all clinicians who are challenged to provide the best care and new opportunities for patients with dyslipidemias. Further adjusted for previous cardiovascular event. The results from the present and earlier studies suggest that the role of the metabolic syndrome on progression to microalbuminuria is modest, whereas at later stages the metabolic syndrome plays a larger role. Section solely to indicate this fact. Click here to view. Covering the full range of common through rare lipid disorders, this timely resource offers targeted, practical information for all clinicians who care for patients with dyslipidemias, including general internists, pediatric and adult endocrinologists, pediatricians, lipidologists, cardiologists, internists, and geneticists.
Om du fortsätter att använda den här webbplatsen accepterar du användandet av cookies.
CardioMetabolic Profile I – test för hjärt-kärlhälsa
National Center for Biotechnology InformationU. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. A major limitation was the incomplete follow-up data on mortality, which was due to the ongoing nature of the FinnDiane Study. The metabolic syndrome in type 1 diabetes: The costs of publication of this article were defrayed in part by the payment of page charges.